Category: Moderna
-
Moderna calls itself the “true innovator” in response to CureVac mRNA patent lawsuit, cites broken non-assert promise
Moderna has filed a response to CureVac’s mRNA patent suit, denying infringement, attacking the validity of all 10 patents, and calling the lawsuit “ultimately a meritless attempt to claim success for work it never did”.
-
Awaiting potential $1.3B Moderna payout, Arbutus expands Covid-19 patent fight to Pfizer, BioNTech in Canada and UPC
Arbutus and Genevant have filed new lawsuits against Pfizer and BioNTech in Canada and the UPC over lipid nanoparticle patents, days after collecting $178 million from their Moderna settlement.
-
Covid-19 vaccine makers Moderna and Pfizer hit with Sanofi suits over mRNA delivery tech
Sanofi and Translate Bio effectively abandoned their own Covid-19 vaccine effort in 2021 after the former acquired the latter.
-
Moderna appeals to save $1.3 billion patent dispute payout, asserts U.S. government-contractor immunity
Moderna has alleged that a district court’s conclusions in a case against Arbutus are “deeply flawed” and that the U.S. Congress created Section 1498 specifically to shield government contractors from liability for government-authorized patent use in fulfilling a government procurement contract.
-
Moderna, Genevant, Arbutus settle global mRNA patent infringement dispute
Moderna could have to pay up to $2.25 billion as part of the settlement agreement, but remains confident it will close 2026 with up to $5 billion in cash and cash equivalents as a result of the deal.
-
New COVID-19 vaccine patent suit: BioNTech v. Moderna
BioNTech has sued Moderna in the United States District Court for the District of Delaware, alleging that the defendant’s most profitable vaccine mNexspike infringes on its key RNA technology.
-
Bayer adds to COVID patent wars: sues Pfizer/BioNTech, Moderna, J&J over mRNA technologyÂ
Bayer’s Monsanto has sued Pfizer/BioNTech, Moderna, and Johnson & Johnson over the alleged infringement of a patent related to gene sequencing technology through their COVID-19 vaccinations.
-
Moderna, Alnylam settle U.S. COVID vaccine patent infringement dispute
Alnylam has settled its three-year dispute against Moderna in the District of Delaware, after a precedential Federal Circuit decision found the patentee had acted as its own lexicographer in defining a key patent specification term, foreclosing its infringement allegations.